{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T22:41:26Z","timestamp":1776206486466,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.eclinm.2025.103383","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T15:21:50Z","timestamp":1753456910000},"page":"103383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Obinutuzumab induction and maintenance in patients with Waldenstr\u00f6m macroglobulinaemia: an open-label, single-arm phase 2 study"],"prefix":"10.1016","volume":"86","author":[{"given":"Tomasz","family":"Wr\u00f3bel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Kalici\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Maciej","family":"Zaucha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Morawska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Giannopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Jamroziak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Lech-Mara\u0144da","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Taszner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Szeremet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartosz","family":"Ma\u0142ecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Druzd-Sitek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"\u0141ojko-Dankowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Dytfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.eclinm.2025.103383_bib1","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamaoncol.2016.5763","article-title":"Diagnosis and management of Waldenstr\u00f6m macroglobulinaemia: mayo stratification of macroglobulinaemia and risk-adapted therapy (mSMART) guidelines 2016","volume":"3","author":"Kapoor","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103383_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.14196","article-title":"Recommendations for the diagnosis and initial evaluation of patients with Waldenstr\u00f6m macroglobulinaemia: a task force from the 8th International Workshop on Waldenstr\u00f6m macroglobulinaemia","volume":"175","author":"Castillo","year":"2016","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103383_bib3","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","article-title":"Consensus treatment recommendations from the tenth International Workshop for Waldenstr\u00f6m macroglobulinaemia","volume":"7","author":"Castillo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103383_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.18036","article-title":"Diagnosis and management of Waldenstr\u00f6m macroglobulinaemia-A British Society for Haematology guideline","volume":"197","author":"Pratt","year":"2022","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.eclinm.2025.103383_bib5","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinaemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.eclinm.2025.103383_bib6","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m's macroglobulinaemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.eclinm.2025.103383_bib7","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinaemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103383_bib8","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinaemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103383_bib9","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/cncr.20658","article-title":"Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstr\u00f6m macroglobulinaemia: an Eastern Cooperative Oncology Group Study","volume":"101","author":"Ghobrial","year":"2004","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103383_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/bjh.13794","article-title":"Rituximab intolerance in patients with Waldenstr\u00f6m macroglobulinaemia","volume":"174","author":"Castillo","year":"2016","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103383_bib11","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1080\/10428190410001714043","article-title":"Multicenter phase 2 trial of rituximab for Waldenstr\u00f6m macroglobulinaemia (WM): an Eastern Cooperative Oncology Group Study (E3A98)","volume":"45","author":"Gertz","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"Supplement_1","key":"10.1016\/j.eclinm.2025.103383_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2019-121909","volume":"134","author":"Rummel","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103383_bib13","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(16)30166-1","article-title":"Once-weekly ofatumumab in untreated or relapsed Waldenstr\u00f6m's macroglobulinaemia: an open-label, single-arm, phase 2 study","volume":"4","author":"Furman","year":"2017","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103383_bib14","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/bloodadvances.2020003895","article-title":"Obinutuzumab and idelalisib in symptomatic patients with relapsed\/refractory Waldenstr\u00f6m macroglobulinaemia","volume":"5","author":"Tomowiak","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103383_bib15","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"10.1016\/j.eclinm.2025.103383_bib16","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103383_bib17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.eclinm.2025.103383_bib18","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103383_bib19","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood-2014-03-565135","article-title":"Treatment recommendations for patients with Waldenstr\u00f6m macroglobulinaemia (WM) and related disorders: IWWM-7 consensus","volume":"124","author":"Dimopoulos","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103383_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.12102","article-title":"Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the VIth International Workshop","volume":"160","author":"Owen","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103383_bib21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood-2015-03-634394","article-title":"Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia","volume":"127","author":"Byrd","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.eclinm.2025.103383_bib22","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab- refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study","volume":"36","author":"Cheson","year":"2018","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.eclinm.2025.103383_bib23","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103383_bib24","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2141.2011.08750.x","article-title":"Maintenance Rituximab is associated with improved clinical outcome in rituximab na\u00efve patients with Waldenstr\u00f6m Macroglobulinaemia who respond to a rituximab-containing regimen","volume":"154","author":"Treon","year":"2011","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103383_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.15148","article-title":"Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstr\u00f6m macroglobulinaemia","volume":"181","author":"Castillo","year":"2018","journal-title":"Br J Haematol"},{"issue":"15_suppl","key":"10.1016\/j.eclinm.2025.103383_bib26","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1200\/JCO.2019.37.15_suppl.7559","article-title":"Rituximab-based maintenance therapy in Waldenstr\u00f6m macroglobulinaemia: a case control study","volume":"37","author":"Zanwar","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103383_bib27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstr\u00f6m's macroglobulinaemia: final analysis from the randomized phase III iNNOVATE study","volume":"40","author":"Buske","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103383_bib28","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ajh.25712","article-title":"Deepening of response after completing rituximab-containing therapy in patients with Waldenstr\u00f6m macroglobulinaemia","volume":"95","author":"Castillo","year":"2020","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103383_bib29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-020-0368-0","article-title":"Informative censoring\u2014a neglected cause of bias in oncology trials","volume":"17","author":"Templeton","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103383_bib30","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1080\/10428190410001723287","article-title":"Treatment of Waldenstr\u00f6m's macroglobulinaemia with rituximab: prognostic factors for response and progression","volume":"45","author":"Dimopoulos","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103383_bib31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/annonc\/mdi022","article-title":"Extended rituximab therapy in Waldenstr\u00f6m's macroglobulinaemia","volume":"16","author":"Treon","year":"2005","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.1016\/j.eclinm.2026.103904","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000}}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T21:42:36Z","timestamp":1776202956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025003153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":31,"alternative-id":["S2589537025003153"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103383","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obinutuzumab induction and maintenance in patients with Waldenstr\u00f6m macroglobulinaemia: an open-label, single-arm phase 2 study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103383"}}